CN112638407A - 重组人类甲状旁腺素的改进稳定性调配物 - Google Patents

重组人类甲状旁腺素的改进稳定性调配物 Download PDF

Info

Publication number
CN112638407A
CN112638407A CN201980056225.XA CN201980056225A CN112638407A CN 112638407 A CN112638407 A CN 112638407A CN 201980056225 A CN201980056225 A CN 201980056225A CN 112638407 A CN112638407 A CN 112638407A
Authority
CN
China
Prior art keywords
formulation
pharmaceutical formulation
rhpth
buffer
physically stable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980056225.XA
Other languages
English (en)
Chinese (zh)
Inventor
N·迪克西特
V·阮
P·苏亚克
S·巴苏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Shire Nps Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Nps Pharmaceutical Co ltd filed Critical Shire Nps Pharmaceutical Co ltd
Publication of CN112638407A publication Critical patent/CN112638407A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980056225.XA 2018-07-30 2019-07-12 重组人类甲状旁腺素的改进稳定性调配物 Pending CN112638407A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862711767P 2018-07-30 2018-07-30
US62/711,767 2018-07-30
PCT/US2019/041609 WO2020028011A1 (en) 2018-07-30 2019-07-12 Formulations for improved stability of recombinant human parathyroid hormone

Publications (1)

Publication Number Publication Date
CN112638407A true CN112638407A (zh) 2021-04-09

Family

ID=69232628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980056225.XA Pending CN112638407A (zh) 2018-07-30 2019-07-12 重组人类甲状旁腺素的改进稳定性调配物

Country Status (9)

Country Link
US (1) US20210315978A1 (https=)
EP (1) EP3829625A4 (https=)
JP (2) JP7399382B2 (https=)
KR (1) KR20210038618A (https=)
CN (1) CN112638407A (https=)
AU (1) AU2019315807B2 (https=)
CA (1) CA3107105A1 (https=)
TW (1) TWI831813B (https=)
WO (1) WO2020028011A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102885113B1 (ko) 2018-10-18 2025-11-13 머크 샤프 앤드 돔 엘엘씨 항-rsv 항체의 제제 및 그의 사용 방법
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
US20230190880A1 (en) * 2020-03-30 2023-06-22 Sichuan Luzhou Buchang Bio-Pharmaceutical Co., Ltd. Formulations of Human Parathyroid Hormone (PTH) and Methods for Producing Same
WO2025032376A1 (en) * 2023-08-04 2025-02-13 Precise Biopharma Pvt Ltd A room temperature stable solution for injection of abaloparatide

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011572A (zh) * 2007-02-02 2007-08-08 重庆科润生物医药研发有限公司 一种重组人甲状旁腺激素(1－84)药物组合物及其制备方法
CN101189025A (zh) * 2005-06-03 2008-05-28 财团法人牧岩生命工学研究所 包含甲状旁腺激素、缓冲剂和稳定剂的稳定的甲状旁腺激素组合物
WO2009053106A1 (en) * 2007-10-26 2009-04-30 Nycomed Danmark Aps Parathyroid hormone formulations and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
EP1030658A1 (en) 1997-10-14 2000-08-30 Eli Lilly And Company Method of building and maintaining bone
WO2013108235A1 (en) * 2012-01-20 2013-07-25 Lupin Limited Stabilized pth formulation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101189025A (zh) * 2005-06-03 2008-05-28 财团法人牧岩生命工学研究所 包含甲状旁腺激素、缓冲剂和稳定剂的稳定的甲状旁腺激素组合物
US20090305965A1 (en) * 2005-06-03 2009-12-10 Kwan-Yub Kang Stabilized Parathyroid Hormone Composition Comprising Parathyroid Hormone, Buffer and Stabilizing Agent
CN101011572A (zh) * 2007-02-02 2007-08-08 重庆科润生物医药研发有限公司 一种重组人甲状旁腺激素(1－84)药物组合物及其制备方法
WO2009053106A1 (en) * 2007-10-26 2009-04-30 Nycomed Danmark Aps Parathyroid hormone formulations and uses thereof

Also Published As

Publication number Publication date
EP3829625A1 (en) 2021-06-09
WO2020028011A1 (en) 2020-02-06
TW202019461A (zh) 2020-06-01
TWI831813B (zh) 2024-02-11
JP2024003211A (ja) 2024-01-11
KR20210038618A (ko) 2021-04-07
AU2019315807B2 (en) 2025-07-10
US20210315978A1 (en) 2021-10-14
EP3829625A4 (en) 2022-08-10
CA3107105A1 (en) 2020-02-06
JP7738046B2 (ja) 2025-09-11
AU2019315807A1 (en) 2021-02-18
JP7399382B2 (ja) 2023-12-18
JP2021532110A (ja) 2021-11-25

Similar Documents

Publication Publication Date Title
JP7738046B2 (ja) 組換えヒト副甲状腺ホルモンの安定性を向上させるための製剤
US20210315961A1 (en) Stable formulations for parenteral injection of peptide drugs
TWI614025B (zh) 速效胰島素組合物
CA2780554C (en) Formulation for hgh and rhigf-1 combination
US9707275B2 (en) Stable aqueous composition comprising human insulin or an analogue or derivative thereof
KR101991756B1 (ko) Ｆｓｈ의 안정화 방법
JP4699991B2 (ja) 非イオン性界面活性剤を一緒に伴うｆｓｈ及びｌｈの液体医薬組成物
JP2021532110A5 (https=)
HK40050341A (en) Formulations for improved stability of recombinant human parathyroid hormone
US20200197494A1 (en) Peptide compositions and methods of use
JPWO2020028011A5 (https=)
HK1175711B (en) Formulation for hgh and rhigf-1 combination

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40050341

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20230418

Address after: Massachusetts

Applicant after: Takeda Pharmaceutical Industry Co.,Ltd.

Address before: Massachusetts

Applicant before: Shire NPs Pharmaceutical Co.,Ltd.

TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20230814

Address after: Osaka, Japan

Applicant after: TAKEDA PHARMACEUTICAL CO.,LTD.

Address before: Massachusetts

Applicant before: Takeda Pharmaceutical Industry Co.,Ltd.

TA01 Transfer of patent application right